Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa , Tim Meyer , Ann‐Lii Cheng , Ghassan K. Abou‐Alfa , Tim Meyer , Ann‐Lii Cheng , Anthony B. El-Khoueiry , Lorenza Rimassa , Baek‐Yeol Ryoo , İrfan Çiçin , Philippe Merle , Yen-Hsun Chen , Joong‐Won Park , Jean-Frederic Blanc , Luigi Bolondi , Heinz‐Josef Klümpen , Stephen L. Chan , Vittorina Zagonel , Tiziana Pressiani , Min-Hee Ryu , Alan P. Venook , Colin Hessel , Anne E. Borgman-Hagey , Gisela Schwab , Robin Kate Kelley
2018 New England Journal of Medicine 2,228 citations

Abstract

Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than placebo. The rate of high-grade adverse events in the cabozantinib group was approximately twice that observed in the placebo group. (Funded by Exelixis; CELESTIAL ClinicalTrials.gov number, NCT01908426 .).

Keywords

CabozantinibSorafenibHepatocellular carcinomaMedicineOncologyInternal medicineTyrosine-kinase inhibitorCarcinomaVascular endothelial growth factorTyrosine kinasePlaceboCancer researchVEGF receptorsReceptorPathologyCancer

Affiliated Institutions

Related Publications

Publication Info

Year
2018
Type
article
Volume
379
Issue
1
Pages
54-63
Citations
2228
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2228
OpenAlex

Cite This

Ghassan K. Abou‐Alfa, Tim Meyer, Ann‐Lii Cheng et al. (2018). Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. New England Journal of Medicine , 379 (1) , 54-63. https://doi.org/10.1056/nejmoa1717002

Identifiers

DOI
10.1056/nejmoa1717002